Norbert W. Bischofberger Buys 90,931 Shares of Kronos Bio, Inc. (NASDAQ:KRON) Stock

Kronos Bio, Inc. (NASDAQ:KRON – Get Rating) CEO Norbert W. Bischofberger acquired 90,931 shares of the firm’s stock in a transaction on Tuesday, May 17th. The stock was purchased at an average price of $3.83 per share, with a total value of $348,265.73. Following the acquisition, the chief executive officer now owns 303,411 shares of the company’s stock, valued at approximately $1,162,064.13. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

NASDAQ KRON traded down $0.21 during mid-day trading on Thursday, reaching $3.55. 3,334,489 shares of the stock were exchanged, compared to its average volume of 347,157. Kronos Bio, Inc. has a 1 year low of $3.50 and a 1 year high of $28.42. The business’s 50 day moving average is $6.09 and its 200-day moving average is $9.70.

Kronos Bio (NASDAQ:KRON – Get Rating) last posted its quarterly earnings results on Thursday, February 24th. The company reported ($1.13) EPS for the quarter, missing the consensus estimate of ($1.07) by ($0.06). On average, equities analysts expect that Kronos Bio, Inc. will post -2.85 EPS for the current year.

Institutional investors have recently modified their holdings of the business. Acadian Asset Management LLC purchased a new position in Kronos Bio in the first quarter valued at about $25,000. Royal Bank of Canada boosted its position in shares of Kronos Bio by 60.2% in the second quarter. Royal Bank of Canada now owns 3,658 shares of the company’s stock worth $88,000 after buying an additional 1,375 shares during the period. Citigroup Inc. boosted its stake in shares of Kronos Bio by 134.0% in the third quarter. Citigroup Inc. now owns 5,046 shares of the company’s stock valued at $106,000 after purchasing an additional 2,890 shares during the period. Quantbot Technologies LP boosted its stake in Kronos Bio by 148.0% during the 1st quarter. Quantbot Technologies LP now owns 6,695 shares of the company’s stock valued at $48,000 after acquiring an additional 3,995 shares during the last quarter. Finally, Trexquant Investment LP bought a new position in shares of Kronos Bio in the 3rd quarter worth about $208,000. 86.97% of the stock is currently owned by institutional investors.

Several equities research analysts recently issued reports on KRON shares. HC Wainwright restated a “buy” rating and issued a $36.00 target price on shares of Kronos Bio in a report on Tuesday, March 8th. Piper Sandler decreased their target price on Kronos Bio from $50.00 to $30.00 and set an “overweight” rating on the stock in a research report on Sunday, February 27th. Finally, Zacks Investment Research downgraded shares of Kronos Bio from a “buy” rating to a “hold” rating in a report on Tuesday, May 10th.

About Kronos Bio (Get Rating)

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients.

Read More